Abstract PS5-05-05: Correlating time to treatment discontinuation with overall survival: real-world data on outcomes for first-line endocrine therapy + CDK4/6 inhibitor in metastatic breast cancer
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Institutions: Dana-Farber Cancer Institute, AstraZeneca (United States)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129501155
Cites:
Cited by:
Related to: